Program
Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969
In AbbVie’s pipeline, PSMA,STEAP1
. Its studies are mostly in Prostatic Neoplasms, led by AbbVie.
Furthest: phase 1, since Mar 13, 20241 company-led study, 1 open or runningNext primary completion: May 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 1since Mar 13, 2024 | Mar 13, 2024 | May 2027phase 1 · NCT06318273 |
- Named in AbbVie’s own pipeline as
ABBV-969
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 13, 2024First study: phase 1 study in Metastatic Castration-Resistant Prostate CancerFirst studyNCT06318273 · 152 enrolled · United States, Australia, Canada and more
Ahead
- May 2027Primary completion: phase 1 study in Metastatic Castration-Resistant Prostate CancerNCT06318273
TargetBeta
“PSMA,STEAP1”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06318273Metastatic Castration-Resistant Prostate Cancer · United States, Australia, Canada and more | 1 | Active, not recruiting | May 2027 | 152 |
How it is read
Names in the registry
- “ABBV-969”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.